# Nectar Lifesciences Ltd.

NecLife

Ref No. NLL/CS/2017- 215

Dated: 04-12-2017

To
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block - G, Bandra Kurla Complex,
Bandra (East), MUMBAI – 400 051.

**Ref.: Your Letter No. NSE/CM/Surveillance/7174 dated December 01, 2017**
**Sub: Increase in Volume**

Dear Sir,

This is with reference your captioned letter regarding the cited subject. In this regard, we would like to confirm that there is no such announcement or price sensitive information which is pending to be intimated / furnished by the Company to the Stock Exchanges Concerning the operations / performance of the Company.

It seems that the increase in volume / price of Equity shares of the Company is purely market driven.

We wish to reiterate and clarify that all information furnished by the Company is in the public domain and that the Company will comply with the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and keep the Stock Exchanges duly informed of all the price sensitive information(s).

You are requested to take the above clarification on record.

Thanking you,
Yours faithfully,

For Nectar Lifesciences Limited

Ankita Jain
Company Secretary

Corporate Office : S.C.O. 38-39, Sector 9-D, Chandigarh-160 009 (India) Tel. : +91-172-3047777 Fax : +91-172-3047755
E-mail : sales@neclife.com Website : www.neclife.com
CIN : L24232 PB1995 PLC 016664
**Regd. Office & Works : Vill. Saidpura, Teh. Dera Bassi, Distt. Mohali (Punjab) Near Chandigarh (INDIA)**
**Tel. : +91-1762-308000, 308001 Fax : +91-1762-281187, 308135**